Sword Group | Confirmation of 2023 Annual Performance - Reassessment of organic growth outlook 2024 - 2028


Werte in diesem Artikel
Aktien

29.95 EUR -0.40 EUR -1.32 %

Consolidated Revenue: €281.6m (i)
Organic Growth: +19% (i)
EBITDA Margin: 12.3% (i)
(i) on a like-for-like basis and at constant exchange rates (excluding AAA)

Werbung


ANALYSIS

Our organic growth for 2023 exceeded our budget forecasts by four percentage points, a significant result which reflects our dynamic expansion. Initially projected at 15%, our organic growth reached 19% (i).

During the second half of the year, our cash collection was particularly strong. Taking into account our portfolio of treasury shares, our cash position increased significantly, from €15.8 million at 30 June 2023 to €32.6 million at 31 December 2023.


OUTLOOK

Our revised business plan for 2024-2028 forecasts annual organic growth of around 15%, with stable profitability of close to 12%.

We will be presenting a detailed strategic plan at our SFAF meeting on 7 March in Paris. Based on these projections, we expect to achieve revenue in excess of €320 million by 2024, continuing our organic growth dynamic.

Dividend

Dividend proposed to the Annual General Meeting: €1.7 per share


Sword has 3,000+ IT/Digital specialists active in 50+ countries to accompany you in the growth of your organisation in the digital age.

As a leader in technological and digital transformation, Sword has a solid reputation in complex IT & business project management.

Sword optimises your processes and enhances your data.


Agenda

25/04/24

2024 First Quarter Revenue

29/04/24

Annual Shareholders Meeting

2023 Accounts

contact



Attachment


Werbung

SWORD GROUP Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für SWORD GROUP nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"

Keine Analysen gefunden.